$XOS
Xos, Inc.

2024 Q4 Form 10-Q Financial Statement

#000181949324000194 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $15.79M
YoY Change -5.43%
Cost Of Revenue $12.93M
YoY Change -12.13%
Gross Profit $2.864M
YoY Change 44.28%
Gross Profit Margin 18.14%
Selling, General & Admin $9.936M
YoY Change -1.57%
% of Gross Profit 346.93%
Research & Development $2.619M
YoY Change -42.01%
% of Gross Profit 91.45%
Depreciation & Amortization $800.0K
YoY Change -57.89%
% of Gross Profit 27.93%
Operating Expenses $12.56M
YoY Change -14.07%
Operating Profit -$9.691M
YoY Change -23.24%
Interest Expense -$607.0K
YoY Change -56.33%
% of Operating Profit
Other Income/Expense, Net -$710.0K
YoY Change -58.86%
Pretax Income -$10.51M
YoY Change -25.5%
Income Tax $4.000K
% Of Pretax Income
Net Earnings -$10.51M
YoY Change -25.48%
Net Earnings / Revenue -66.57%
Basic Earnings Per Share -$1.32
Diluted Earnings Per Share -$1.32
COMMON SHARES
Basic Shares Outstanding 8.029M shares 8.004M shares
Diluted Shares Outstanding 7.984M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.432M
YoY Change -62.69%
Cash & Equivalents $8.400M
Short-Term Investments
Other Short-Term Assets $9.762M
YoY Change 30.16%
Inventory $42.40M
Prepaid Expenses
Receivables $36.44M
Other Receivables $0.00
Total Short-Term Assets $97.58M
YoY Change 6.67%
LONG-TERM ASSETS
Property, Plant & Equipment $16.24M
YoY Change -22.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.694M
YoY Change 276.28%
Total Long-Term Assets $22.94M
YoY Change 1.0%
TOTAL ASSETS
Total Short-Term Assets $97.58M
Total Long-Term Assets $22.94M
Total Assets $120.5M
YoY Change 5.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.920M
YoY Change 266.93%
Accrued Expenses $4.393M
YoY Change -28.24%
Deferred Revenue $620.0K
YoY Change -36.21%
Short-Term Debt $2.087M
YoY Change 19.94%
Long-Term Debt Due $21.44M
YoY Change 116.58%
Total Short-Term Liabilities $50.19M
YoY Change 84.72%
LONG-TERM LIABILITIES
Long-Term Debt $496.0K
YoY Change -97.74%
Other Long-Term Liabilities $18.94M
YoY Change 112.61%
Total Long-Term Liabilities $18.94M
YoY Change 112.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $50.19M
Total Long-Term Liabilities $18.94M
Total Liabilities $69.67M
YoY Change 23.04%
SHAREHOLDERS EQUITY
Retained Earnings -$184.4M
YoY Change 32.28%
Common Stock $1.000K
YoY Change -94.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.84M
YoY Change
Total Liabilities & Shareholders Equity $120.5M
YoY Change 5.54%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$10.51M
YoY Change -25.48%
Depreciation, Depletion And Amortization $800.0K
YoY Change -57.89%
Cash From Operating Activities -$11.52M
YoY Change 33.61%
INVESTING ACTIVITIES
Capital Expenditures $148.0K
YoY Change -177.89%
Acquisitions
YoY Change
Other Investing Activities $125.0K
YoY Change -99.11%
Cash From Investing Activities -$23.00K
YoY Change -100.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K
YoY Change -100.4%
NET CHANGE
Cash From Operating Activities -11.52M
Cash From Investing Activities -23.00K
Cash From Financing Activities 40.00K
Net Change In Cash -11.50M
YoY Change 158.43%
FREE CASH FLOW
Cash From Operating Activities -$11.52M
Capital Expenditures $148.0K
Free Cash Flow -$11.67M
YoY Change 38.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
251000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9840000 usd
CY2024Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-107000 usd
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
315000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10508000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14104000 usd
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001819493
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Type
DocumentType
10-Q
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36441000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15142000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
45196000 usd
dei Entity Address Address Line1
EntityAddressAddressLine1
3550 Tyburn Street
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8029344 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11640000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
754000 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1330000 usd
CY2024Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16 shares
CY2024Q2 xos Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
0.64
CY2024Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.46
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2247000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5887000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6308000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-31302000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1726000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8432000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
42398000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7070000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8920000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2756000 usd
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90065
dei City Area Code
CityAreaCode
818
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8025000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8025000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
14610000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9691000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12625000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-710000 usd
CY2024Q3 xos Derivative Instrument Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability
0 usd
CY2023Q3 xos Derivative Instrument Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability
68000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10512000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14107000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
0 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
56000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7984000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5876000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7984000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5876000 shares
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
171000 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0333
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39598
dei Entity Registrant Name
EntityRegistrantName
XOS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1550505
dei Local Phone Number
LocalPhoneNumber
316-1890
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q4 us-gaap Inventory Net
InventoryNet
37843000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9552000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
97577000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
71695000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
12480000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
14660000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3762000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4991000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6694000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2338000 usd
CY2024Q3 us-gaap Assets
Assets
120513000 usd
CY2023Q4 us-gaap Assets
Assets
93684000 usd
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
19957000 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21310000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
16817000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
50187000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19573000 usd
CY2024Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 usd
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
19920000 usd
CY2024Q3 xos Derivative Instrument Contingent Consideration Liability
DerivativeInstrumentContingentConsiderationLiability
6000 usd
CY2023Q4 xos Derivative Instrument Contingent Consideration Liability
DerivativeInstrumentContingentConsiderationLiability
39000 usd
CY2024Q3 xos Warrants And Rights Outstanding Noncurrent
WarrantsAndRightsOutstandingNoncurrent
542000 usd
CY2023Q4 xos Warrants And Rights Outstanding Noncurrent
WarrantsAndRightsOutstandingNoncurrent
395000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18937000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8561000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
69672000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
48488000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5941000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5941000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
235279000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
198456000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184439000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153261000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
50841000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
45196000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120513000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93684000 usd
CY2024Q3 us-gaap Revenues
Revenues
15790000 usd
CY2023Q3 us-gaap Revenues
Revenues
16696000 usd
us-gaap Revenues
Revenues
44487000 usd
us-gaap Revenues
Revenues
26147000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
12926000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
14711000 usd
us-gaap Cost Of Revenue
CostOfRevenue
36805000 usd
us-gaap Cost Of Revenue
CostOfRevenue
28764000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
2864000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
1985000 usd
us-gaap Gross Profit
GrossProfit
7682000 usd
CY2022Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
20000000 usd
CY2024Q3 xos Capital Stock Shares Authorized
CapitalStockSharesAuthorized
1010000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 xos Common Stock Voting Rights Number Of Votes
CommonStockVotingRightsNumberOfVotes
1 vote
us-gaap Gross Profit
GrossProfit
-2617000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8897000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8546000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27032000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29961000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2619000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4516000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8691000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15446000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1039000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1548000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3261000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5113000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
12555000 usd
us-gaap Operating Expenses
OperatingExpenses
38984000 usd
us-gaap Operating Expenses
OperatingExpenses
50520000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-53137000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-147000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
525000 usd
xos Derivative Instrument Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability
-33000 usd
xos Derivative Instrument Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability
-443000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31165000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62009000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31178000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62016000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
0 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
739000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10512000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14051000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31178000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61277000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.81
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7321000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5738000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7321000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5738000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
112075000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1987000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
382000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23929000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
89751000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2037000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
374000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
212000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
924000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23297000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
69260000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q2 xos Debt Instrument Redemption Prepayment Reduction Period Prior To Prepayment Date
DebtInstrumentRedemptionPrepaymentReductionPeriodPriorToPrepaymentDate
P30D
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5500 shares
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
138794 shares
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
46750 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
1201885 usd
CY2024Q3 xos Sale Of Stock Remaining Commitment Amount Available
SaleOfStockRemainingCommitmentAmountAvailable
119400000 usd
CY2023Q4 xos Sale Of Stock Remaining Commitment Amount Available
SaleOfStockRemainingCommitmentAmountAvailable
119500000 usd
CY2024Q3 xos Sale Of Stock Number Of Shares Registered For Resale
SaleOfStockNumberOfSharesRegisteredForResale
3333333 shares
xos Class Of Warrant Or Right Fair Market Value Threshold Consecutive Trading Days Ending On Third Trading Day Prior To Notice Of Redemption
ClassOfWarrantOrRightFairMarketValueThresholdConsecutiveTradingDaysEndingOnThirdTradingDayPriorToNoticeOfRedemption
P10D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1834 shares
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.56
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.63
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M10D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7184 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1834 shares
CY2024Q3 xos Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue
0.56
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.63
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M10D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7184 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2242000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
278000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14051000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
57560000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1968000 usd
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
258000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
31856000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11003000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
67806000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1634000 usd
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
563000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9663000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
59224000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2247000 usd
CY2024Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
118000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10512000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
50841000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31178000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62016000 usd
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
2551000 usd
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
3096000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1229000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1165000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
37000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5127000 usd
xos Amortization Of Insurance Premiums
AmortizationOfInsurancePremiums
2125000 usd
xos Amortization Of Insurance Premiums
AmortizationOfInsurancePremiums
3415000 usd
xos Inventory Reserve Increase Decrease
InventoryReserveIncreaseDecrease
-812000 usd
xos Inventory Reserve Increase Decrease
InventoryReserveIncreaseDecrease
-1155000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
131000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1476000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-147000 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
525000 usd
xos Derivative Instrument Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability
-33000 usd
xos Derivative Instrument Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentChangeInAmountOfContingentConsiderationLiability
-443000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-91000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5887000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6308000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-356000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
157000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21337000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3226000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3934000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9456000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3591000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3717000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2620000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
180000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5395000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-451000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-6446000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3081000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
141000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
190000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52093000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38655000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
304000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1164000 usd
us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
125000 usd
us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
1295000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
50720000 usd
xos Cash Acquired From Asset Acquisition
CashAcquiredFromAssetAcquisition
51355000 usd
xos Cash Acquired From Asset Acquisition
CashAcquiredFromAssetAcquisition
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
51176000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50851000 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
1738000 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
2476000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
3107000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
3770000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
2024000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
4096000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
23800000 usd
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0 usd
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1190000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
939000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
927000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1202000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1537000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-27509000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2454000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15313000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11640000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38675000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9186000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23362000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8432000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22570000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
754000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
792000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9186000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23362000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
1431000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
16000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
xos Increase Decrease In Capital Expenditures Accrual
IncreaseDecreaseInCapitalExpendituresAccrual
-35000 usd
xos Increase Decrease In Capital Expenditures Accrual
IncreaseDecreaseInCapitalExpendituresAccrual
14000 usd
xos Conversion Of Interest Payable On Convertible Debentures
ConversionOfInterestPayableOnConvertibleDebentures
0 usd
xos Conversion Of Interest Payable On Convertible Debentures
ConversionOfInterestPayableOnConvertibleDebentures
12000 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
200000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
54630000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 usd
us-gaap Stock Issued1
StockIssued1
31856000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52100000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38700000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39300000 usd
CY2024Q3 xos Sale Of Stock Number Of Shares Registered For Resale
SaleOfStockNumberOfSharesRegisteredForResale
3333333 shares
CY2022Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
20000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenues and expenses during the reporting periods. The areas with significant estimates and judgments include, among others, inventory valuation, incremental borrowing rates for assessing operating and financing lease liabilities, useful lives of property and equipment, stock-based compensation, product warranty liability, and valuation of convertible debt and related embedded derivatives, common stock warrant liability, earn-out shares liability and valuations utilized in connection with acquisitions. Management bases its estimates on historical experience and on </span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.</span></div>
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
72000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
62000 usd
CY2024Q3 us-gaap Receivable For Recovery Of Import Duties Net
ReceivableForRecoveryOfImportDutiesNet
2700000 usd
CY2024Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1143000 usd
CY2023Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1301000 usd
CY2023Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1306000 usd
CY2022Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1099000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
394000 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
280000 usd
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1316000 usd
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1024000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
419000 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
309000 usd
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1178000 usd
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1255000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1168000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1168000 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1330000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit and Business Risk</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of September 30, 2024 and 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></div>
xos Defined Contribution Plan Auto Enrollment Contributions Per Employee Percent
DefinedContributionPlanAutoEnrollmentContributionsPerEmployeePercent
0.03
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22512 shares
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.40
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.51
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y6M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
168194 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20659 shares
CY2024Q1 xos Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
0.38
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.50
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
141076 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1853 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.56
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.63
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M14D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17806 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
115 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1837 shares
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.56
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.63
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M14D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11532 usd
CY2024Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3 shares
CY2024Q3 xos Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
0.64
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.46
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13 usd
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0 usd
CY2024Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0 usd
CY2024Q3 us-gaap Revenues
Revenues
15790000 usd
CY2023Q3 us-gaap Revenues
Revenues
16696000 usd
us-gaap Revenues
Revenues
44487000 usd
us-gaap Revenues
Revenues
26147000 usd
CY2024Q3 us-gaap Severance Costs1
SeveranceCosts1
0 usd
us-gaap Severance Costs1
SeveranceCosts1
2000000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
42400000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
37800000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
29875000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
30357000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
8840000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3033000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3683000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4453000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
42398000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
37843000 usd
CY2024Q3 xos Prepaid Inventory
PrepaidInventory
3479000 usd
CY2023Q4 xos Prepaid Inventory
PrepaidInventory
1745000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1690000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1291000 usd
CY2024Q3 xos Lease Receivable Current
LeaseReceivableCurrent
1662000 usd
CY2023Q4 xos Lease Receivable Current
LeaseReceivableCurrent
1505000 usd
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
544000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
811000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
2025000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1310000 usd
CY2024Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
152000 usd
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
408000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9552000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7070000 usd
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
2954000 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
1599000 usd
CY2024Q3 us-gaap Receivable For Recovery Of Import Duties Net
ReceivableForRecoveryOfImportDutiesNet
2709000 usd
CY2023Q4 us-gaap Receivable For Recovery Of Import Duties Net
ReceivableForRecoveryOfImportDutiesNet
0 usd
CY2024Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
1031000 usd
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
739000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6694000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2338000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4393000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5539000 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
4285000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2532000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1896000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
620000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
690000 usd
CY2024Q3 xos Deposits Of Customers Current
DepositsOfCustomersCurrent
1321000 usd
CY2023Q4 xos Deposits Of Customers Current
DepositsOfCustomersCurrent
2364000 usd
CY2024Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1168000 usd
CY2023Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1306000 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
390000 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
350000 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
2087000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
1003000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3030000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1664000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1484000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2005000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21310000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
16817000 usd
xos Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
600000 usd
xos Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
400000 usd
CY2023 xos Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
400000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
595000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
2985000 usd
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
304000 usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
593000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17542000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3511000 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
496000 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1472000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18937000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8561000 usd
CY2021Q3 xos Derivative Instrument Contingent Consideration Liability Shares
DerivativeInstrumentContingentConsiderationLiabilityShares
540000 shares
CY2024Q3 xos Derivative Instrument Contingent Consideration Liability
DerivativeInstrumentContingentConsiderationLiability
6000 usd
CY2023Q4 xos Derivative Instrument Contingent Consideration Liability
DerivativeInstrumentContingentConsiderationLiability
39000 usd
xos Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability
33000 usd
xos Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability
400000 usd
CY2024Q3 xos Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability
0 usd
CY2023Q3 xos Derivative Instrument Gain Loss Change In Amount Of Contingent Consideration Liability
DerivativeInstrumentGainLossChangeInAmountOfContingentConsiderationLiability
-100000 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
20000000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2200000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5900000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2200000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6300000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2242000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12700000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M28D
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
23441000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
22662000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
10961000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
8002000 usd
CY2024Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
12480000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
14660000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
800000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
1900000 usd
us-gaap Depreciation
Depreciation
2600000 usd
us-gaap Depreciation
Depreciation
3300000 usd
CY2024Q3 xos Unrecorded Unconditional Purchase Obligation Number Of Vendors
UnrecordedUnconditionalPurchaseObligationNumberOfVendors
2 vendor
CY2024Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
300000 usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0004
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0004
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0002
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10512000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14107000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31178000 usd
us-gaap Net Income Loss
NetIncomeLoss
-62016000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10512000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14107000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31178000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62016000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10512000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14107000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31178000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-62016000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7984000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5876000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7321000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5738000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.81
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7984000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5876000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7321000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5738000 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.81
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001819493-24-000194-index-headers.html Edgar Link pending
0001819493-24-000194-index.html Edgar Link pending
0001819493-24-000194.txt Edgar Link pending
0001819493-24-000194-xbrl.zip Edgar Link pending
ex-311xceosec302certificat.htm Edgar Link pending
ex-312xcfosec302certificat.htm Edgar Link pending
ex-321xceocfosec906certifi.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xos-20240930.htm Edgar Link pending
xos-20240930.xsd Edgar Link pending
xos-20240930_g1.jpg Edgar Link pending
xos-20240930_cal.xml Edgar Link unprocessable
xos-20240930_def.xml Edgar Link unprocessable
xos-20240930_lab.xml Edgar Link unprocessable
xos-20240930_pre.xml Edgar Link unprocessable
xos-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable